Has Bantwal Baliga, MD received payments from drug or device companies?

Yes. Drug and device makers reported $482,685 in general payments to Bantwal Baliga, MD across 1,912 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bantwal Baliga, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bantwal Baliga, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bantwal Baliga, MD

Endocrinology, Diabetes & Metabolism · Opelika, ALNPI 1992847669

Payments from drug & device makers

$482,685in general payments, 2019–2025

Across 1,912 payments — averaging $252.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$129K
Novo Nordisk$120K
Abbott$77K
Boehringer Ingelheim$42K
AstraZeneca$37K
Amarin Pharma, Inc.$30K
plus $47K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	318	$128,973
Novo Nordisk	265	$119,652
Abbott	279	$77,289
Boehringer Ingelheim	84	$42,023
AstraZeneca(2 entities)	129	$36,963
Amarin Pharma, Inc.	51	$30,472
Ascensia Diabetes Care US Inc.	25	$11,131
Senseonics, Incorporated	17	$5,278
Merck	34	$5,220
Xeris Pharmaceuticals, Inc.	115	$4,620
BETA Bionics, Inc.	42	$2,889
Bigfoot Biomedical Inc	38	$2,736
Bayer	56	$2,020
Tandem Diabetes Care, Inc.	21	$1,973
Zealand Pharma US, Inc.	58	$1,936
Medtronic(3 entities)	54	$1,520
Mannkind Corporation	34	$1,147
Amgen(2 entities)	54	$882
Valeritas, Inc.	33	$843
Dexcom, Inc.	14	$559
Corcept Therapeutics	26	$479
Sanofi-aventis U.S. LLC	22	$448
Kyowa Kirin, Inc.	8	$367
Cequr Corporation	2	$334
IBSA Pharma Inc.	12	$228
Sequel Med Tech, LLC	4	$208
Ascendis Pharma Endocrinology Inc	6	$206
Vivus LLC	5	$180
Amneal Pharmaceuticals LLC	11	$169
Intuity Medical Inc	5	$168
Companion Medical, Inc.	6	$161
AbbVie	10	$154
Akebia Therapeutics Inc	1	$124
Ultragenyx Pharmaceutical Inc.	8	$119
Esperion Therapeutics, Inc.	7	$112
Amphastar Pharmaceuticals, Inc.	5	$102
Radius Health, Inc.	6	$98
Insulet Corporation	4	$77
Recordati_rare_diseases_inc.	3	$77
Nevro Corp.	1	$75
Neurocrine Biosciences, Inc.	3	$63
GSK	3	$52
Rhythm Pharmaceuticals, Inc.	3	$52
Antares Pharma, Inc.	2	$43
Takeda Pharmaceuticals U.S.A., Inc.	2	$40
Kowa Pharmaceuticals America, Inc.	3	$38
Pfizer	2	$34
Tolmar, Inc.	2	$33
Johnson & Johnson	2	$26
Averitas Pharma Inc.	1	$25
Shire North American Group Inc	1	$25
Soleno Therapeutics, Inc.	1	$22
ARS Pharmaceuticals Operations, Inc.	1	$20
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$18
Acella Pharmaceuticals, LLC	1	$18
Eisai Inc.	1	$18
Clarus Therapeutics Inc.	1	$17
Lifescan, Inc.	1	$16
Sumitomo Pharma America, Inc.	1	$16
Siemens Medical Solutions USA, Inc.	1	$16

How this compares

$482,685 in reported general payments places this provider in the 90th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

See all endocrinology, diabetes & metabolism providers in Alabama →

Medicare billing

Part B allowed, 2024

$374,689

Medicare patients

747

Services billed

20,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Opelika

Neil SchaffnerOpelika$642K
William GarveyBirmingham$3.8M
Fernando OvalleBirmingham$516K
Ralph TeagueBirmingham$487K
Judson MenefeeFairhope$185K
Amy WarrinerBirmingham$182K
William DebellTuscaloosa$161K
Edison GoncalvesBirmingham$142K
Bruce TrippeDothan$136K
David BellIrondale$112K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →